JP7606537B2 - 神経筋疾患の処置のためのピリダジノン化合物 - Google Patents

神経筋疾患の処置のためのピリダジノン化合物 Download PDF

Info

Publication number
JP7606537B2
JP7606537B2 JP2022568794A JP2022568794A JP7606537B2 JP 7606537 B2 JP7606537 B2 JP 7606537B2 JP 2022568794 A JP2022568794 A JP 2022568794A JP 2022568794 A JP2022568794 A JP 2022568794A JP 7606537 B2 JP7606537 B2 JP 7606537B2
Authority
JP
Japan
Prior art keywords
alkyl
optionally substituted
halogen
compound
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022568794A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023526248A5 (cg-RX-API-DMAC10.html
JP2023526248A (ja
Inventor
ケビン コック,
ケビン ハント,
スティーブン シュラクター,
アラン ラッセル,
Original Assignee
エッジワイズ セラピューティクス, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エッジワイズ セラピューティクス, インコーポレイテッド filed Critical エッジワイズ セラピューティクス, インコーポレイテッド
Publication of JP2023526248A publication Critical patent/JP2023526248A/ja
Publication of JP2023526248A5 publication Critical patent/JP2023526248A5/ja
Priority to JP2024218934A priority Critical patent/JP7715911B2/ja
Application granted granted Critical
Publication of JP7606537B2 publication Critical patent/JP7606537B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2022568794A 2020-05-13 2021-05-12 神経筋疾患の処置のためのピリダジノン化合物 Active JP7606537B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024218934A JP7715911B2 (ja) 2020-05-13 2024-12-13 神経筋疾患の処置のためのピリダジノン化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063024439P 2020-05-13 2020-05-13
US63/024,439 2020-05-13
PCT/US2021/031979 WO2021231565A1 (en) 2020-05-13 2021-05-12 Pyridazinone compounds for the treatment of neuromuscular diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024218934A Division JP7715911B2 (ja) 2020-05-13 2024-12-13 神経筋疾患の処置のためのピリダジノン化合物

Publications (3)

Publication Number Publication Date
JP2023526248A JP2023526248A (ja) 2023-06-21
JP2023526248A5 JP2023526248A5 (cg-RX-API-DMAC10.html) 2024-05-22
JP7606537B2 true JP7606537B2 (ja) 2024-12-25

Family

ID=76284178

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022568794A Active JP7606537B2 (ja) 2020-05-13 2021-05-12 神経筋疾患の処置のためのピリダジノン化合物
JP2024218934A Active JP7715911B2 (ja) 2020-05-13 2024-12-13 神経筋疾患の処置のためのピリダジノン化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024218934A Active JP7715911B2 (ja) 2020-05-13 2024-12-13 神経筋疾患の処置のためのピリダジノン化合物

Country Status (4)

Country Link
US (1) US12643892B2 (cg-RX-API-DMAC10.html)
EP (2) EP4473968A3 (cg-RX-API-DMAC10.html)
JP (2) JP7606537B2 (cg-RX-API-DMAC10.html)
WO (1) WO2021231565A1 (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102885525B1 (ko) 2018-11-06 2025-11-13 엣지와이즈 테라퓨틱스, 인크. 피리다지논 화합물 및 이의 용도
SMT202300355T1 (it) 2018-11-06 2024-01-10 Edgewise Therapeutics Inc Composti di piridazinone e loro usi
WO2020097258A1 (en) 2018-11-06 2020-05-14 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof
EP4473968A3 (en) 2020-05-13 2025-03-26 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof
WO2023091606A1 (en) * 2021-11-17 2023-05-25 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof
AU2023254325B2 (en) * 2022-04-15 2026-06-04 Wuhan Humanwell Innovative Drug Research and Development Center Limited Company Kif18a inhibitor and use thereof
KR20250174911A (ko) 2023-03-27 2025-12-15 엣지와이즈 테라퓨틱스, 인크. 퀴놀리논 아미드 화합물 및 이의 용도
JP7858148B1 (ja) 2023-03-27 2026-05-13 エッジワイズ セラピューティクス, インコーポレイテッド キナゾリンジオン化合物およびその使用
WO2025207665A1 (en) * 2024-03-26 2025-10-02 Edgewise Therapeutics, Inc. Quinolinone compounds and uses thereof
WO2025207622A1 (en) * 2024-03-26 2025-10-02 Edgewise Therapeutics, Inc. Quinolinone, benzoxazinone, and quinoline compounds and uses thereof
WO2025207677A1 (en) * 2024-03-26 2025-10-02 Edgewise Therapeutics, Inc. Quinazolinone compounds and uses thereof
WO2025207679A1 (en) * 2024-03-26 2025-10-02 Edgewise Therapeutics, Inc. Quinazoline dione compounds and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011133888A1 (en) 2010-04-23 2011-10-27 Cytokinetics, Inc. Certain amino-pyrimidines, compositions thereof, and methods for their use
US20120289698A1 (en) 2011-04-22 2012-11-15 Ashcraft Luke W Certain heterocycles, compositions thereof, and methods for their use
US20180280385A1 (en) 2017-03-28 2018-10-04 Boehringer Ingelheim International Gmbh Nintedanib for use in methods for the treatment of muscular dystrophy
WO2019084499A1 (en) 2017-10-27 2019-05-02 Genea Biocells USA (Holdings), Inc. INHIBITORS OF DUX4 INDUCTION FOR REGULATION OF MUSCLE FUNCTION

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE286354C (cg-RX-API-DMAC10.html)
JPS6140270A (ja) 1984-08-01 1986-02-26 Morishita Seiyaku Kk ピリダジノン誘導体
ATE180475T1 (de) 1990-09-21 1999-06-15 Rohm & Haas Dihydropyridazinone und pyridazinone als fungizide
US5376667A (en) * 1992-12-31 1994-12-27 Entropin, Inc. Derivatives of benzoylecgonine, ecgonine and their multiple pharmacological properties
KR100477070B1 (ko) 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
IL118631A (en) 1995-06-27 2002-05-23 Tanabe Seiyaku Co History of pyridazinone and processes for their preparation
DE19629817A1 (de) 1996-07-24 1998-01-29 Hoechst Ag Neue Imino-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
CN1471515A (zh) 2000-06-05 2004-01-28 ��̹��ҽҩ��˾ 作为β2-肾上腺素受体激动剂及PDE-4抑制剂的有效的化合物
WO2004022540A2 (en) 2002-09-06 2004-03-18 Fujisawa Pharmaceutical Co., Ltd. Pyridazinone and pyridone derivatives as adenosine antagonists
MXPA05009500A (es) 2003-03-07 2005-10-18 Kowa Co Derivado de benzofurano.
US7763617B2 (en) 2005-03-07 2010-07-27 Kyorin Pharmaceutical Co., Ltd. Pyrazolopyridine-4-yl pyridazinone derivatives and addition salts thereof, and PDE inhibitors comprising the same derivatives or salts as active ingredient
WO2007044796A2 (en) 2005-10-11 2007-04-19 Nps Pharmaceuticals, Inc. Pyridazinone compounds as calcilytics
DE102005057924A1 (de) 2005-12-05 2007-06-06 Merck Patent Gmbh Pyridazinonderivate
EP2502918B1 (en) 2006-07-25 2015-03-25 Cephalon, Inc. Pyridazinone Derivatives
CA2676173A1 (en) 2007-02-16 2008-08-28 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
DE102007025717A1 (de) 2007-06-01 2008-12-11 Merck Patent Gmbh Arylether-pyridazinonderivate
DE102007025718A1 (de) 2007-06-01 2008-12-04 Merck Patent Gmbh Pyridazinonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
DE102007038957A1 (de) 2007-08-17 2009-02-19 Merck Patent Gmbh 6-Thioxo-pyridazinderivate
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
EP2328586A2 (en) 2008-05-20 2011-06-08 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
WO2012021707A2 (en) 2010-08-11 2012-02-16 The Regents Of The University Of California Premature-termination-codons readthrough compounds
ES2537190T3 (es) 2010-09-01 2015-06-03 Gilead Connecticut, Inc. Piridazinonas, procedimiento de preparación y procedimientos de utilización de las mismas
EP2768826A1 (de) 2011-10-17 2014-08-27 Bayer Intellectual Property GmbH Substituierte oxadiazolylpyridinone und - pyridazinone als hif - hemmer
CN103570730A (zh) 2012-08-01 2014-02-12 中国科学院上海药物研究所 具有桥环结构的稠环哒嗪酮类化合物及其制备方法和用途
WO2014031928A2 (en) 2012-08-24 2014-02-27 Philip Jones Heterocyclic modulators of hif activity for treatment of disease
US9566310B2 (en) 2012-09-10 2017-02-14 Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Reno Methods of treating muscular dystrophy
WO2014055644A2 (en) 2012-10-02 2014-04-10 New York University Pharmaceutical compositions and treatment of genetic diseases associated with nonsense mediated rna decay
JP2016507496A (ja) 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションZenith Epigenetics Corp. ブロモドメイン阻害剤としての新規複素環式化合物
JP6483624B2 (ja) 2013-02-07 2019-03-13 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung ピリダジノン−アミド誘導体
EP2968323A4 (en) 2013-03-13 2016-12-14 Flatley Discovery Lab PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
CN105636645A (zh) 2013-04-19 2016-06-01 爱荷华大学研究基金会 在肌萎缩症中的血管紧张素
CA2987980A1 (en) 2015-06-05 2016-12-08 Ptc Therapeutics, Inc. Use of an aminoglycoside for nonsense mutation suppression and the treatment of disease
EP3307891B8 (en) 2015-06-10 2019-11-13 Association Institut de Myologie Combined therapy for duchenne muscular dystrophy
CN106467495A (zh) 2015-08-19 2017-03-01 中国科学院上海药物研究所 哒嗪酮类化合物、其制备方法、药物组合物及用途
WO2017046117A1 (en) 2015-09-15 2017-03-23 Abbvie Inc. Substituted isoxazolopyridazinones and isothiazolopyridazinones and methods of use
US20190248779A1 (en) 2016-10-26 2019-08-15 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
CA3041676A1 (en) 2016-10-26 2018-05-03 Daniel Parks Pyridazine derivatives, compositions and methods for modulating cftr
EP3532461A1 (en) 2016-10-26 2019-09-04 Proteostasis Therapeutics, Inc. N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis
TWI886480B (zh) 2017-04-06 2025-06-11 美商富曼西公司 殺真菌之噁二唑
US20180303821A1 (en) 2017-04-24 2018-10-25 BraneQuest, Inc. Membrane active molecules
BE1025518B1 (fr) 2017-08-30 2019-04-03 E2 Drives Sa Groupe motopropulseur
US11236052B2 (en) 2017-09-06 2022-02-01 Translational Drug Development, Llc Aminobenzimidazole derivatives, treatments, and methods of inhibiting histone deacetylase
MX2020012243A (es) 2018-05-17 2021-01-29 Bolt Threads Inc Cepas modificadas con sec para una mejor secrecion de proteinas recombinantes.
ES3041367T3 (en) 2018-06-04 2025-11-11 Ohio State Innovation Foundation Eaat2 activators and methods of using thereof
EP3828174A4 (en) 2018-07-19 2022-08-17 Sumitomo Pharma Co., Ltd. PYRIDAZINONE DERIVATIVE
CN108947912B (zh) 2018-07-31 2021-10-01 中国人民解放军总医院 一种靶向Neddylation通路的抗肿瘤化合物
SMT202300355T1 (it) 2018-11-06 2024-01-10 Edgewise Therapeutics Inc Composti di piridazinone e loro usi
KR102885525B1 (ko) * 2018-11-06 2025-11-13 엣지와이즈 테라퓨틱스, 인크. 피리다지논 화합물 및 이의 용도
WO2020097258A1 (en) * 2018-11-06 2020-05-14 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof
EP4149467A1 (en) 2020-05-13 2023-03-22 Edgewise Therapeutics, Inc. Substituted pyridazinone for use in the treatment of neuromuscular diseases
EP4149465A1 (en) 2020-05-13 2023-03-22 Edgewise Therapeutics, Inc. Substituted pyridazinone for use in the treatment of neuromuscular diseases
WO2021231630A1 (en) 2020-05-13 2021-11-18 Edgewise Therapeutics, Inc. Substituted pyridazinone for use in the treatment of neuromuscular diseases
WO2021231572A1 (en) 2020-05-13 2021-11-18 Edgewise Therapeutics, Inc. Pyridazinone compounds for the treatment of neuromuscular diseases
EP4473968A3 (en) 2020-05-13 2025-03-26 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof
JP7694135B2 (ja) 2021-05-11 2025-06-18 株式会社大林組 接続構造及び接続方法
WO2023091606A1 (en) 2021-11-17 2023-05-25 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof
WO2023220180A1 (en) 2022-05-11 2023-11-16 Edgewise Therapeutics, Inc. Methods of manufacturing pyridazinone compounds
JP2025530218A (ja) 2022-09-09 2025-09-11 エッジワイズ セラピューティクス, インコーポレイテッド 神経筋の状態の処置のためのピリダジノン組成物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011133888A1 (en) 2010-04-23 2011-10-27 Cytokinetics, Inc. Certain amino-pyrimidines, compositions thereof, and methods for their use
US20120289698A1 (en) 2011-04-22 2012-11-15 Ashcraft Luke W Certain heterocycles, compositions thereof, and methods for their use
US20180280385A1 (en) 2017-03-28 2018-10-04 Boehringer Ingelheim International Gmbh Nintedanib for use in methods for the treatment of muscular dystrophy
WO2019084499A1 (en) 2017-10-27 2019-05-02 Genea Biocells USA (Holdings), Inc. INHIBITORS OF DUX4 INDUCTION FOR REGULATION OF MUSCLE FUNCTION

Also Published As

Publication number Publication date
US20230159513A1 (en) 2023-05-25
US12643892B2 (en) 2026-06-02
WO2021231565A1 (en) 2021-11-18
JP2023526248A (ja) 2023-06-21
JP2025032327A (ja) 2025-03-11
EP4473968A3 (en) 2025-03-26
EP4473968A2 (en) 2024-12-11
EP4149620B1 (en) 2024-10-23
JP7715911B2 (ja) 2025-07-30
EP4149620A1 (en) 2023-03-22

Similar Documents

Publication Publication Date Title
JP7715911B2 (ja) 神経筋疾患の処置のためのピリダジノン化合物
JP7429750B2 (ja) ピリダジノン化合物およびその使用
JP7357135B2 (ja) ピリダジノン化合物およびその使用
JP7758687B2 (ja) 神経筋疾患の処置のためのピリダジノン化合物
US12240833B2 (en) Pyridazinone compounds and uses thereof
US20230293518A1 (en) Substituted pyridazinones for use in the treatment of neuromuscular diseases
US20230338375A1 (en) Substituted pyridazinones for use in the treatment of neuromuscular diseases
US20230321091A1 (en) Substituted pyridazinones for use in the treatment of neuromuscular diseases
JP2024540485A (ja) ピリダジノン化合物およびその使用
EA050889B1 (ru) Соединения пиридазинонов и их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240510

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240510

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20240510

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240910

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241115

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241213

R150 Certificate of patent or registration of utility model

Ref document number: 7606537

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150